This MedLibrary.org supplementary page on Bapineuzumab is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
|
Bapineuzumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Humanized |
| Target | ? |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C6466H10018N1734O2026S44 |
| Mol. mass | 148.8 kDa (major glycoform) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.1
Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for the first iteration of the drug, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques and quality of life increases, but 6% of subjects developed aseptic meningitis and the trial was stopped.2
Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and entered Phase III trials in December 2007.3
References
- ^ Sample, Ian (2007-08-07). "New Alzheimer's drugs might help prevent glaucoma" (in English). The Guardian, http://www.guardian.co.uk/science/2007/aug/07/3. Retrieved on 18 June 2008.
- ^ Woodhouse, Adele; Dickson, Tracey C.; Vickers, James C. (2007). "Vaccination strategies for Alzheimer's disease: A new hope?" (in English). Drugs & Aging (Mairangi Bay, Auckland, New Zealand: Adis International) 24 (2): 107–119. doi:. ISSN 1170-229X. PMID 17313199, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17313199. Retrieved on 18 June 2008. "The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.".
- ^ Elan Corporation (2008-06-17). "Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease" (in English). Press release. Retrieved on 2008-06-18. “Elan and Wyeth plan to continue all four studies in the previously disclosed bapineuzumab Phase 3 clinical program”
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 2 November 2008, at 06:27.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Bapineuzumab".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.